We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NGF

News List

Pfizer, Eli Lilly’s non-opioid drug helps reduce osteoarthritis pain biospectrumasia
November 26, 2018
A non-opioid drug developed by Pfizer and Eli Lilly met the main goals of a late-stage study, in which over half of the patients reported a significant reduction in osteoarthritis pain of the knee or hip.
Pfizer & Lilly's non-opioid drug reduces pain in osteoarthritis pharmafile
October 25, 2018
Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of its co-primary endpoints in the treatment of osteoarthritis (OA).
Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain firstwordpharma
October 25, 2018
Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain